IBIndranil Banerjee

Indranil Banerjee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Indranil Banerjee has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Modified PAMAM Dendrimer-Based Carboplatin Delivery in Glioblastoma: In Vitro and In Vivo Studies

    by Madhurima Mandal, Dipanjan Samanta, Debolina Manna, Deblina Bharadwaj, Ranabir Majumder, Indranil Banerjee, Budhaditya Mukherjee, Mahitosh Mandal

    The complex neoplasm of central nervous system malignancies, glioblastoma multiforme (GBM), is often challenging to manage due to its location complexity and anatomical barriers. The majority of conventional anticancer drugs are restricted by the blood-brain barrier, except Temozolomide, which also hampers patients' quality of life. Therefore, a potential carrier system is needed to enhance drug delivery efficiency. In this study, we have prepared the nanoformulation G4PFCP, a G4 PAMAM_OH dendrimer functionalized with folic acid and conjugated with carboplatin, to evaluate its efficacy in drug delivery to the GBM tumor microenvironment. Both the drug loaded (G4PFCP) and drug free (G4PF) nanoparticles have been characterized by spectroscopic and microscopic techniques. They have exhibited properties that are consistent with pH-specific sustained drug release. Both in vivo and in vitro studies have been performed. G4PFCP exhibited enhanced therapeutic efficacy compared to free carboplatin and G4PF in LN18 and LN229 GBM cell lines, which has been evaluated based on induced nuclear fragmentation and chromatin condensation. Furthermore, treatment with G4PFCP led to significant modulation of apoptotic markers, including Cleaved Caspase-9, XIAP, Bax, and DSB protein γ-H2AX. In the rat model, G4PFCP treatment resulted in substantial tumor size reduction and notable antiproliferative and antiangiogenic effects without showing any organ toxicity. The findings suggest that the G4PFCP nanoformulation represents a promising and effective drug delivery system for targeting GBM malignancies.


  • Effective approaches in conquering chemoresistance of glioblastoma: potential for nanoformulations

    by Madhurima Mandal, Indranil Banerjee, Mahitosh Mandal

    Glioblastoma Multiforme is an aggressive and complex cancer affecting mostly elderly patients above the age of 60 years. Originally classified as the fourth stage of glioma, it has an abysmal prognosis along with limited therapeutic options. Surgical removal of tumors, radiotherapy, and chemotherapy are prevalent treatment strategies with numerous therapeutic obstacles, including undefined boundary of tumor mass leaving traces even after excision, chances of secondary cancer formation, and presence of blood–brain barrier. These blood–brain and blood–brain tumor barriers actively restrict the permeability of many molecules from blood circulation to enter the central nervous system. Therefore, many conventional antineoplastic drugs fail to reach the tumor periphery except temozolomide. Meanwhile, active stem cells in the tumor microenvironment, genetic mutation inducing tumor growth, and epigenetic pattern alteration make this cancer chemoresistant. Our review delineates the recent approaches to resensitize the existing clinical drugs through specifically designed nanoformulations. Nanoparticles with modified physiological characteristics and modified through technological parameters can reduce the tumor's stemness, which increases tumor cells' apoptosis rate. Moreover, these nanoparticles can efficiently traverse the blood–brain barrier and escape from endosomal degradation with minimum toxicological impact. Overall, this review discusses the cancer chemoresistance phenomena and related pathways and highlights the potential of nanoformulation in reversing chemoresistance. Also, the existing limitations of this unique approach and suggestions are discussed at the end of the article, which may facilitate the identification of new directions for advancement of the nanoparticle-mediated reversal of chemoresistance. Graphical Abstract


  • Open Access

    NANOEMULSION AS A DRUG DELIVERY SYSTEM OF ANTICANCER DRUG

    by Soumik Maity, Indranil Banerjee

    Nanoemulsions are isotropic systems made up of nanoscale droplets (about 200 nm in size) created by combining two immiscible liquids with the aid of emulsifiers. They are often regarded as harmless excipients and are made to enhance the release of active medicinal compounds. Improving drug distribution to specific areas is the main goal of employing nanoemulsions in cancer treatment. In addition to increasing bioavailability, nanoemulsions reduce adverse effects on healthy cells by encasing medications in a closed structure. This is especially crucial because, in the absence of such formulations, different medications fall short of their intended targets. The study shows that by increasing the solubility and bioavailability of anticancer medications, nanoemulsions can greatly improve their delivery. This is important because a lot of anticancer medications have low solubility, which reduces their ability to effectively target cancer cells. Nanoemulsions have been shown to effectively target tumor cells while minimizing the impact on healthy tissues. This targeted approach helps overcome the common issue of multidrug resistance seen in cancer treatments, as the nanoemulsions can be modified with specific ligands to focus on tumor cells. Targeting tumor cells and preventing multidrug resistance are two benefits of using nanoemulsions. Besides, hydrophilic and hydrophobic compounds can be encapsulated in nanoemulsions to satisfy a range of needs. Therefore, nanoemulsions are a promising new approach to cancer treatment. This review provides an overview of nanoemulsion in cancer therapeutics, aiming to highlight the current status of this technology.


  • Paracrine TGF-β1 from breast cancer contributes to chemoresistance in cancer associated fibroblasts via upregulation of the p44/42 MAPK signaling pathway

    by Bikash Chandra Jena, Chandan Kanta Das, Indranil Banerjee, Subhayan Das, Deblina Bharadwaj, Ranabir Majumder, Mahitosh Mandal


  • Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma

    by Yetirajam Rajesh, Angana Biswas, Utkarsh Kumar, Indranil Banerjee, Subhayan Das, Santanu Maji, Swadesh K. Das, Luni Emdad, Webster K. Cavenee, Mahitosh Mandal, et al.

    Significance: No current therapies prevent recurrence in patients with glioblastoma multiforme (GBM). Extracellular matrix (ECM) remodeling and epithelial mesenchymal transition (EMT) are important processes regulating GBM progression and acquisition of radiation and temozolomide (radio/TMZ) resistance. Fli-1 choreographs ECM remodeling and EMT in GBM via transcriptional regulation of HSPB1. Lumefantrine, an antimalarial drug, inhibits the transcriptional activities of Fli-1 and its downstream targets HSPB1, ECM remodeling, and EMT. Lumefantrine is selectively cytotoxic and promotes apoptosis in GBM and reverses radio/TMZ resistance in GBM. This drug can easily be repurposed for management of GBM. Identification of drugs like lumefantrine from FDA-approved therapeutic agents and uncommon sources provides opportunities to broaden the breadth and versatility of current therapeutic regimens for GBM.


  • Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma

    by Y. Rajesh, Angana Biswas, Utkarsh Kumar, Subhayan Das, Indranil Banerjee, Payel Banik, Rashmi Bharti, Santoshi Nayak, Sudip K. Ghosh, Mahitosh Mandal


  • A peptide-modified solid lipid nanoparticle formulation of paclitaxel modulates immunity and outperforms dacarbazine in a murine melanoma model

    by Indranil Banerjee, Manjarika De, Goutam Dey, Rashmi Bharti, Sankha Chattopadhyay, Nahid Ali, Partha Chakrabarti, Rui L. Reis, Subhas C. Kundu, Mahitosh Mandal

    Melanoma is a highly aggressive skin cancer. A paclitaxel formulation of solid lipid nanoparticles modified with Tyr-3-octreotide (PSM) is employed to treat melanoma that highly expresses somatostatin receptors (SSTRs). PSM exerts more apoptotic and anti-invasive effects in B16F10 mice melanoma cells as compared to dacarbazine (DTIC), an approved chemotherapeutic drug for treating aggressive melanoma. Besides, PSM induces one of the biomarkers of immunogenic cell death in vitro and in vivo as confirmed by calreticulin exposure on the B16F10 cell surface. We observed a significant number of CD8 positive T cells in the tumor bed of the PSM treated group. As a result, PSM effectively reduces tumor volume in vivo as compared to DTIC. PSM also induces a favorable systemic immune response as determined in the spleen and sera of the treated animals. Importantly, PSM can reduce the number of nodule formations in the experimental lung metastasis model. Our experimentations indicate that the metronomic PSM exhibits remarkable anti-melanoma activities without any observable toxicity. This immune modulation behavior of PSM can be exploited for the therapy of melanoma and probably for other malignancies.


  • Exosome as a Novel Shuttle for Delivery of Therapeutics across Biological Barriers

    by Chandan Kanta Das, Bikash Chandra Jena, Indranil Banerjee, Subhayan Das, Aditya Parekh, Sujit Kumar Bhutia, Mahitosh Mandal

    The effective delivery of target-specific siRNA to the brain by exploiting the exosomes derived from dendritic cells renders the paradigm shift for the prospective use of nanosized exosomes as a delivery system. Although the in vivo targeting strategies by other nanovesicles like liposomes exist, still this novel exosome-based delivery approach holds an inclusive dominance of in vivo security and reduced immunogenicity. Achieving promising exosome-based delivery strategies warrants more desirable exploration of their biology. Over the years, the invention of novel production, characterization, targeting strategies, and cargo loading techniques of exosome improved its ability to reach clinics. Essentially, exosome-based delivery of therapeutics assures to conquer the major hurdles like delivery of cargos across impermeable biological barriers like blood-brain barrier, biocompatibility, increased solubility, metabolic stability, improved circulation time, target specific delivery, pharmacokinetics, and thereby enhanced the efficacy of loaded therapeutic agents. In this article, we cover the current status of exosome as a delivery vehicle for therapeutics, challenges that need to be overcome, and also discuss future perspectives of this exciting field of research to transform it from bench to clinical reality.


  • Open Access

    A Novel Therapeutic Strategy for Cancer Using Phosphatidylserine Targeting Stearylamine-Bearing Cationic Liposomes

    by Manjarika De, Sneha Ghosh, Triparna Sen, Md. Shadab, Indranil Banerjee, Santanu Basu, Nahid Ali